Skip to main content

Table 1 Exosomes as AD biomarkers in discussed studies

From: Mesenchymal stem cell-derived exosome: a promising alternative in the therapy of Alzheimer’s disease

Source

Body fluid

Isolation methods

Validation techniques

Direction of protein change

Ref.

Neuronal

Plasma

EXOQ + anti-L1CAM immunocapture

TEM, NTA

ADC and AD: P-T181-tau, P-S396-tau, and Aβ1–42 ↑, NRGN, REST ↓ compared to CNC and stable MCI patients

[53]

Neurally

Plasma or serum

EXOQ + anti-NCAM immunocapture

NTA

AD: total Tau, P-T181-tau, P-S396-tau and Aβ1–42 ↑compared to controls

FTD: P-T181-tau and Aβ1–42 ↑ compared to controls

[54]

Neuronal

Plasma

or CSF

EXOQ + anti-NCAM immunocapture

TEM, WB

AD: Aβ42, T-tau, and P-T181-tau ↑ compared to aMCI and control groups

The level of each exosomal biomarker was highly correlated with that in CSF

[55]

Neuronal

Plasma

EXOQ + anti-L1CAM immunocapture

NTA, TEM, WB

AD and FTD: synaptophysin, synaptopodin, synaptotagmin-2, and neurogranin ↓ compared to controls

AD: GAP43, synapsin 1 ↓ synaptotagmin, synaptophysin, and neurogranin were correlated with MMSE or ADAS-cog

[56]

Neurally

Plasma

EXOQ + anti-L1CAM immunocapture

NTA

AD: cathepsin D, LAMP-1, ubiquitinylated proteins ↑, and HSP70 ↓ compared to controls and FTD

[57]

Neuronal

Plasma

EXOQ + anti-L1CAM immunocapture

NTA, TEM, WB

AD:NPTX2, NRXN2α, AMPA4, NLGN1 ↓

Preclinical period: NRXN2α, AMPA4, and NLGN1 ↓ compared to controls

[58]

Astrocyte

Plasma

EXOQ + anti-ACSA-1 immunocapture

NTA, TEM, WB

AD: complement proteins, IL-6, TNF-α, IL-1β ↑; complement regulatory proteins (CD59, CD46, DAF), complement receptor type 1 ↓ compared to controls

[59]

Astrocyte

Plasma

EXOQ + anti-ACSA-1 immunocapture

NTA

AD: BACE-1, (s)APPβ ↑, GDNF ↓ compared to controls

FTD: compared to controls n. d.

[60]

  1. ↑ higher; ↓ lower; n. d. no difference compared to control, EXOQ ExoQuick exosome precipitation solution, L1CAM neural adhesion protein, TEM transmission electron microscope, NTA Nanoparticle Tracking Analysis, MCI mild cognitive impairment, ADC MCI converting to AD, REST repressor element 1-silencing transcription factor, NRGN neurogranin, ADAS-cog AD assessment scale-cognitive subscale, CNC cognitively normal controls, FTD frontotemporal dementia, GAP43growth-associated protein 43, MMSE Mini-Mental State Examination, LAMP-1 lysosome-associated membrane protein 1, HSP70 heat-shock protein 70, ACSA-1 antihuman glutamine aspartate transporter, NPTX2 neuronal pentraxin 2, NRXN2α neurexin 2α, AMPA4 GluA4-containing glutamate, NLGN1 receptor and neuroligin 1, TNF-α tumor necrosis factor-α, DAF decay-accelerating factor, BACE-1 β-site amyloid precursor protein-cleaving enzyme 1, (s)APP soluble amyloid precursor protein, GDNF glial-derived neurotrophic factor